Named on one round in the feed.
Since 2020-02-06
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Azafaros Azafaros develops therapeutics for patients with rare metabolic disorders, particularly those affecting the lysosomal storage system. | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $27.5M | 2020-02-06 | [ PART ] |